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We measured serum anti-pneumolysin IgG concentrations in a prospective cohort of 34 HIV infected
adults who developed recurrent pneumococcal bacteraemia, and compared baseline levels with HIV pos-
itive and HIV negative control subjects that remained free of pneumococcal disease. Anti-pneumolysin
concentrations in HIV positive cases and controls were higher compared to HIV negative controls. There
was no signiﬁcant difference in levels between HIV positive subjects who did and did not subsequentlyKeywords:
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develop pneumococcal bacteraemia (geometric means 849.1U/ml vs. 564.6U/ml, p=0.059). Anti-
pneumolysin IgG titres before, and after the recurrent episode of pneumococcal bacteraemia did not differ
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. Introduction
HIV infected individuals have higher rates of severe, recur-
ent pneumococcal disease compared to HIV uninfected adults [1],
ontributing to the morbidity and mortality with advanced HIV
isease. A recently performed clinical trial has recently shown
hat a seven-valent pneumococcal conjugate vaccine is effec-
ive for the secondary prevention of disease in HIV infected
dults caused by vaccine serotypes (N. French in preparation,
resented at ISPPD6). However, because of the limited serotype
overage of currently available pneumococcal conjugate polysac-
haride vaccines, an improved vaccine strategy to provide broad
rotection against pneumococcal infection is sought. Protein and
rotein–polysaccharide components are amongst promising anti-
ens for new pneumococcal vaccines.
Streptococcus pneumoniae expresses a potent toxin, pneu-
olysin. This cytosolic protein is released during bacterial growth
nd lysis [2,3]. As pneumolysin is common to virtually all S. pneu-
oniae isolates, toxoided derivatives of pneumolysin are mainandidates for a protein-based or protein-polysaccharide conjugate
neumococcal vaccine for humans [4].
Antibodies to pneumolysin are produced early in life in response
o pneumococcal carriage and infection [5,6]. The protective effect
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at an effective immune response has occurred in HIV infected patients.
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of vaccination with pneumolysin against pneumococcal infection
has been demonstrated in animal studies [6]. In humans, colo-
nized subjects and patients with nonbacteraemic pneumococcal
pneumonia had higher levels of IgG to pneumolysin compared to
patients with bacteraemic pneumococcal pneumonia suggesting
that early in infection, anti-pneumolysin protects the host against
bacteraemic pneumococcal disease and disease severity [6]. Simi-
larly, in a group of HIV infected patients, a lower baseline level of
antibody to pneumolysin was associated with a higher incidence of
pneumococcal bacteraemia [7].
The antibody response to pneumolysin in recurrent pneu-
mococcal bacteraemia in HIV infected adults has not been
described previously to our knowledge. We measured serum anti-
pneumolysin IgG titres in HIV infected Malawian adults followed
prospectively for recurrence of pneumococcal bacteraemia. Com-
parison was made with HIV negative and HIV positive subjects
remaining free of invasive pneumococcal disease. The aim of the
study was to contribute to experimental information about the
utility of pneumolysin as a vaccine for the prevention of invasive
pneumococcal disease in HIV infected individuals.
2. Methods
Open access under CC BY license.2.1. Subjects and samples
Thirty-four HIV infected patients with a microbiologically con-
ﬁrmed episode of invasive pneumococcal disease were recruited
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rent pneumococcal bacteraemia event. In ﬁve cases post-disease
serawere unavailable for analysis. Demographic and clinical details
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nd followed until they developed a recurrent episode of pneu-
ococcal bacteraemia. These individuals were participants in a
andomised controlled trial of seven-valent pneumococcal protein
onjugate vaccine, in Blantyre, Malawi. Serum samples were taken
t the timeof recruitment and then every threemonths. All 34 cases
ad at least one further episode of pneumococcal bacteraemia dur-
ng the study. Recruitment started in February 2003 and ﬁnished at
he end of May 2007.
HIV infected subjectswithout a history of pneumococcal disease
nd HIV-uninfected subjects were identiﬁed in a separate cohort
f individuals participating in parallel studies of pneumococcal
mmunity in Blantyre. This was an open cohort recruited during
he same interval as the cases and followed up using the same clinic
rotocols as the vaccine trial participants. Each of the 34 cases was
atched individually by age and sex with 1 HIV positive individual
nd 1 HIV negative individual. If there were a number of potential
atches, the individualwith aCD4 cell count closest to the casewas
sed as the control. No episode of invasive pneumococcal disease
as diagnosed in these individuals up to the end of the study.
Samples were collected at the Queen Elizabeth Central Hospi-
al, Blantyre, Malawi. The serum sample selected for analysis as
aseline for the cases was the stored sample that immediately pre-
ated the recurrentpneumococcal event. Serawere storedat−80 ◦C
nd shipped frozen to the Liverpool School of Tropical Medicine
or ELISA analysis. All procedures were conducted with approval
rom the College of Medicine, Research Ethics Committee and with
igned informed consent from each participant.
.2. Measurement of serum anti-pneumolysin IgG
ELISA plates (NUNC, Wiesbaden, Germany) were coated
vernight at 4 ◦C in phosphate buffered saline (PBS) with pneu-
olysin supplied by University of Alabama, Birmingham, USA, at
concentration of 0.94mg/ml. All assays included control wells
oated with a bovine serum albumin (BSA) to verify the speci-
city of the assays for the coating antigen. Plates were washed
ith PBS containing 0.05% Tween 20 (ELISA wash buffer). Plates
ere always washed three times. The plates were blocked with
.1% BSA for one hour at room temperature followed by overnight
ncubation at 4 ◦C with the subject’s sera in serial three-fold dilu-
ions (1:200–1:145800). FollowingwashingwithELISAwashbuffer,
he plates were incubated with biotin conjugated goat anti-human
mmunoglobulin (IgG) serum (Oxford Biotechnology, UK) for two
ours at room temperature, washed and then incubated with
treptavidin–alkaline phosphatase (Oxford Biotechnology, UK) for
ne hour at room temperature. Incubation at room temperature
ccurredwith the plates rocking on a horizontal shaker. After a ﬁnal
able 1
emographics, CD4+ cell count, and anti-pneumolysin antibody titres in HIV infected cas
Cases (n=34) Group
HIV posi
controls
ge (years), mean (s.d.) 35.4 (7.5) 35.0 (8
ex n (Males/Females) 17/17 17/17
D4+ cell count/l: geometric mean (95%
CI)
132.9 (107.5–164.3) 178.2 (12
re-event anti-pneumolysin IgG titre
(U/ml): geometric mean (95% CI)
849.1 (635.8–1134.0) 564.6 (4
ost-event anti-pneumolysin IgG titre
(U/ml): geometric mean (95% CI)
840.2b (610.9–1155.5) –
ean ratio of pre-event anti-pneumolysin
IgG titre to post-event anti- pneumolysin
IgG titre (95% CI)
1.007b (0.818–1.240)b –
a Tukey HSD p-values, adjusted for multiple comparisons.
b n=29.27 (2009) 3881–3884
wash, the plates were developed with p-nitrophenyl phosphate
(Sigma, St. Louis, MO, USA). Absorbance was read at 405nm on
an ELISA reader (Opys MR, Dynex Technologies) with data analysis
software, Revelation Quicklink version 4.25. Assays were standard-
ized using a pooled human serum sample with a known titre of
pneumolysin-speciﬁc IgG. The coefﬁcient of variation for each assay
was <15%.
2.3. HIV test
Serum samples from recruits were tested for HIV by twin ELISA
(Abbott Murex HIV-1.2.2 kit and Vironostika HIV Uni-Form II plus
O kit, bioMerieux). Discordant samples were repeated and if not
resolved were subjected to two rapid tests (Determine, Abbott lab-
oratories, and Uni-Gold, Trinity Biotech, Ireland).
2.4. CD4+ T-cell counts
CD4+ T-cell counts were measured using BD FACScount (Becton
Dickinson) as per manufacturer’s instructions.
2.5. Data analysis
SPSS software (version 14.0, SPSS) was used for analysis of the
data. Antibody concentrations and CD4 counts were converted to
natural logarithms for analysis to obtain approximate normal dis-
tributions, so the results for both measures are reported using
geometric means. Group comparisons were by one way analy-
sis of variance (ANOVA) followed where appropriate by post hoc
Tukey multiple comparison tests. Comparison of pre- and post-
bacteraemia antibody concentrations for the recurrent bacteraemia
group was by paired-samples Student t-tests. Differences between
groups were considered signiﬁcant at the conventional 5% level
(p≤0.05).
3. Results
Thirty-four HIV positive trial participants experienced a recur-for the subjects are summarized in Table 1. There were no sig-
niﬁcant differences between the groups with respect to age and
sex distribution, but as expected the HIV infected groups had
signiﬁcantly lower CD4+ cell counts than did the HIV negative sub-
jects.
es with recurrent pneumococcal bacteraemia and control subjects.
Multiple comparison p-valuesa
tive
(n=34)
HIV negative
controls (n=34)
Cases vs. HIV
positive controls
Cases vs. HIV
negative controls
.5) 32.9 (11.4.) 0.987 0.536
17/17
4.8–254.5) 568.3 (445.4–725.0) 0.286 <0.001
28.6–743.8) 356.1 (296.3–428.0) 0.059 <0.001
– – –
– – –
O.M. Etuwewe et al. / Vaccine 27 (2009) 3881–3884 3883
Fig. 1. Baseline serum IgG antibodies to pneumolysin in HIV positive cases with
recurrent pneumococcal bacteraemia (n=34) matched HIV positive controls (n=34)
and matched HIV negative controls (n=34) displayed as box-and-whisker plots. The
circle represents an outlier (value between 1.5 and 3 interquartile ranges from the
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pnd of the box), asterisks are extreme outliers (>3 interquartile range from box). HIV
ositive cases and HIV positive controls had signiﬁcantly higher IgG titres than HIV
egative controls. There was no signiﬁcant difference in levels between cases and
IV positive controls (p=0.059).
.1. Comparison of baseline anti-pneumolysin IgG titres between
ases and controls
HIVpositive caseshadsigniﬁcantlyhigher anti-pneumolysin IgG
itres than HIV negative subjects (p<0.001). HIV positive controls
lso had signiﬁcantly higher anti-pneumolysin IgG titres than the
IV negative controls (p=0.028). HIV positive cases that had recur-
ence of bacteraemia had a tendency to higher anti-pneumolysin
gG titres compared to HIV positive control subjects (Fig. 1), but
his was not statistically signiﬁcant (p=0.059).
.2. Change in anti-pneumolysin IgG titre in cases after
ecurrence of pneumococcal bacteraemia
Case sera were collected a median time of 40 days before the
ecurrent pneumococcal disease episode (range, 0–334 days), for
aseline anti-pneumolysin IgG measurement. Sera after the recur-
ent bacteraemia episode, were collected at a median time of 39
ays (range, 13–177 days) post-disease. There was no signiﬁcant
hange in anti-pneumolysin IgG titres between baseline level and
ost-bacteraemia episode (p=0.95) (Fig. 2).
.3. Relationship between CD4+ level and anti-pneumolysin IgG
itre
There was no signiﬁcant difference in CD4+T-cell counts
etween HIV positive cases and HIV positive controls (geometric
ean 132.9/l vs. 178.2/l, p=0.29). Aweak but statistically signif-
cant negative correlation was found between CD4+ T-cell number
nd baseline anti-pneumolysin IgG titres in cases and HIV posi-
ive controls (r=0.26, p=0.03). There was no signiﬁcant correlation
etween CD4+ cell count and change in anti-pneumolysin titre in
ases after the bacteraemia episode.. Discussion
In this study, HIV positive subjects in Malawi had higher anti-
neumolysin titres compared to HIV negative controls. BaselineFig. 2. Proﬁle plot of change in speciﬁc IgG titres against pneumolysin before (base-
line) and after the recurrent pneumococcal bacteraemia episode in the 29 caseswith
paired titres.
anti-pneumolysin titres did not differ signiﬁcantly between HIV
positive cases at recruitment after a conﬁrmed pneumococcal bac-
teraemia episode, prior to recurrence, and HIV positive controls
without observed episode of invasive pneumococcal disease. The
anti-pneumolysin titres after recurrence of pneumococcal bacter-
aemia in the cases were not signiﬁcantly different from baseline
values. There was no signiﬁcant correlation between CD4+ T-cell
count and change in anti-pneumolysin titre in cases after the recur-
rent bacteraemia episode.
Previous studies in different populations with HIV infection in
the United States have also reported no signiﬁcant difference in
pre-disease anti-pneumolysin titres between HIV positive cases
suffering pneumococcal bacteraemia and HIV positive controls
without invasive pneumococcal disease [7,8]. However, Amdahl
and colleagues reported lower anti-pneumolysin titres in HIV posi-
tive individuals compared to HIV negative controls, opposite to the
observation in our study. Sullivan and colleagues in their study of a
cohort of intravenous drug users in the United States, found no sig-
niﬁcant difference in pre-disease anti-pneumolysin titres between
cases and HIV negative control subjects [8]. Our study does dif-
fer from Amdahl’s and Sullivan’s as our cases were recruited after
the individual had had an episode of pneumococcal bacteraemia,
and followed up in time during which they suffered a recurrence;
baseline serum anti-pneumolysin titres were obtained in the inter-
val between two pneumococcal bacteraemia episodes. Therefore,
as our cases had already suffered a pneumococcal event, it might
be expected that they would have higher anti-pneumolysin titres.
A recent study of HIV infected African adults reported increased
colonisation rates with S. pneumoniae [9]. Subjects colonized with
S.pneumoniae have also been observed to have higher serum IgG
concentrations to pneumolysin compared to patients with bac-
teraemic pneumococcal bacteraemia [6]. We therefore speculate
that the increased rate of pneumococcal colonisation seen in HIV
positive adults is a likely explanation for the observed higher
anti-pneumolysin titres in HIV infected subjects in our study. We,
however, did not investigate nasopharyngeal pneumococcal car-
riage in this study.
We expected an increase in pneumolysin titres following an
episodeofpneumococcal bacteraemia, asdemonstrated inprevious
studies [6,10]. The change in anti-pneumolysin titres after pneu-
mococcus re-infection in our study was not signiﬁcantly different
compared to baseline values. A weakness in our study could be
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he varying time intervals of sera collection before and after the
ecurrent infection. However, the median time interval of sera col-
ection after the recurrent infection episode was 39 days; we think
t unlikely that the expected rise in anti-pneumolysin titre could
ave been missed because of the timing of sera collection. It could
herefore be suggested thatHIV infected individuals show impaired
esponse in anti-pneumolysin titres following pneumococcal bac-
eraemia. Thismay be a feature of the immune dysregulation inHIV
nfection, which is still not clearly understood.
Mucosal defence against pneumococcal carriage is dependent
n themigrationofCD4+cells to thepulmonarymucosa in response
o pneumolysin [11]. CD4− T-cell-negative mice are signiﬁcantly
ore susceptible to pneumococcal lung infection and bacteraemia
han mice with functional CD4+ T-cells [2]. Furthermore, low CD4+
-cell levels havebeen shown tobe associatedwith increased risk of
acteraemia in HIV infected patients with pneumococcal pneumo-
ia [12]. In our study, the cases and HIV positive control groups had
imilar CD4+ cell counts (geometric mean<200/l) and therefore
he inﬂuence of CD4+ cell level on susceptibility cannot be tested.
HIV infected individuals have higher speciﬁc IgG to pneu-
olysin in serum, in response to natural infection, compared to
IV uninfected subjects. However, invasive pneumococcal dis-
ase is common in HIV infected subjects despite this observed
igher serum anti-pneumolysin titres. This observation of a
uantitative immune response to pneumolysin may offer sup-
ort to a pneumolysoid-based vaccine for HIV infected adults.
owever, these data suggest that pneumolysin antibody alone
ill not protect against naturally acquired invasive pneumo-
occal infection in this group. The role of pneumolysin may
herefore be as an adjuvant or protein carrier of other vaccine
ntigens.
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